The clinical practice of risk reduction for Alzheimer's disease: A precision medicine approach
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Like virtually all age‐related chronic diseases, late‐onset Alzheimer's disease (AD) develops over an extended preclinical period and is associated with modifiable lifestyle and environmental factors. We hypothesize that multimodal interventions that address many risk factors simultaneously and are individually tailored to patients may help reduce AD risk. We describe a novel clinical methodology used to evaluate and treat patients at two Alzheimer's Prevention Clinics. The framework applies evidence‐based principles of clinical precision medicine to tailor individualized recommendations, follow patients longitudinally to continually refine the interventions, and evaluate N‐of‐1 effectiveness (trial registered at ClinicalTrials.gov NCT03687710). Prior preliminary results suggest that the clinical practice of AD risk reduction is feasible, with measurable improvements in cognition and biomarkers of AD risk. We propose using these early findings as a foundation to evaluate the comparative effectiveness of personalized risk management within an international network of clinician researchers in a cohort study possibly leading to a randomized controlled trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072 · cited 3×
“Accumulating evidence suggests that modifiable risk factors for AD can be addressed in an effort to delay onset [20,61,62].”
BackgroundNgandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689 · cited 1×
“Accumulating evidence suggests that modifiable risk factors for AD can be addressed in an effort to delay onset [20,61,62].”
BackgroundBig Data and Machine Learning in Health Care
Beam, A. L., & Kohane, I. S. (2018) · JAMA · doi:10.1001/jama.2017.18391 · Cited by 2,506 · cited 2×
“of clinical care augmented by predictive analytics will most likely fall within the continuum of entirely human-guided versus fully machine-guided patient care [64].”
BackgroundPotential for primary prevention of Alzheimer's disease: an analysis of population-based data
Norton, S., Matthews, F. E., Barnes, D. E., Yaffe, K., & Brayne, C. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70136-x · Cited by 2,466
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 1×
“Evolving evidence has helped define target age groups for implementing risk reduction interventions for AD [5,6].”
BackgroundAndrieu, S., Guyonnet, S., Coley, N., Cantet, C., Bonnefoy, M., Bordes, S., Bories, L., Cufi, M.-N., Dantoine, T., Dartigues, J.-F., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30040-6 · Cited by 838
Mediterranean Diet and Mild Cognitive Impairment
Scarmeas, N., Stern, Y., Mayeux, R., Manly, J. J., Schupf, N., & Luchsinger, J. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.536 · Cited by 757
Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition
Gottesman, R. F., Schneider, A. L. C., Zhou, Y., Coresh, J., Green, E., Gupta, N., Knopman, D. S., Mintz, A., Rahmim, A., Sharrett, A. R., et al. (2017) · JAMA · doi:10.1001/jama.2017.3090 · Cited by 650 · cited 1×
“Several known modifiable factors are associated with increased risk for AD development, such as hypertension and physical inactivity [18,19].”
BackgroundGottesman, R. F., Albert, M. S., Alonso, A., Coker, L. H., Coresh, J., Davis, S. M., Deal, J. A., McKhann, G. M., Mosley, T. H., Sharrett, A. R., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.1658 · Cited by 633
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
Frisoni, G. B., Boccardi, M., Barkhof, F., Blennow, K., Cappa, S., Chiotis, K., Démonet, J.-F., Garibotto, V., Giannakopoulos, P., Gietl, A., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30159-x · Cited by 626 · cited 1×
“used, particularly in research settings [39].”
Kivipelto, M., Solomon, A., Ahtiluoto, S., Ngandu, T., Lehtisalo, J., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.09.012 · Cited by 589 · cited 2×
“This 2-year, multidomain randomized controlled trial found that a combined evidence-based program of a brain-healthy diet, exercise, cognitive training, and stimulating social activity, teamed with careful monitoring of vascular risk, helped improve or maintain cognitive function in an elderly cohort at risk for AD [2…”
BackgroundDisclosure of APOE Genotype for Risk of Alzheimer's Disease
Green, R. C., Roberts, J. S., Cupples, L. A., Relkin, N. R., Whitehouse, P. J., Brown, T., Eckert, S. L., Butson, M., Sadovnick, A. D., Quaid, K. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809578 · Cited by 554
Craft, S. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362137 · Cited by 487
Rosenberg, A., Ngandu, T., Rusanen, M., Antikainen, R., Bäckman, L., Havulinna, S., Hänninen, T., Laatikainen, T., Lehtisalo, J., Levälahti, E., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.09.006 · Cited by 421
Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States
Brookmeyer, R., Abdalla, N., Kawas, C. H., & Corrada, M. M. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.10.009 · Cited by 406 · cited 2×
“Early intervention is especially important as recent estimates have found that more than 46 million Americans currently have preclinical AD [8].”
BackgroundKloppenborg, R. P., van den Berg, E., Kappelle, L. J., & Biessels, G. J. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.02.049 · Cited by 368
Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging
Mosconi, L., Berti, V., Quinn, C., McHugh, P., Petrongolo, G., Varsavsky, I., Osorio, R. S., Pupi, A., Vallabhajosula, S., Isaacson, R. S., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004425 · Cited by 319 · cited 1×
“greater attention to muscle mass in men), but a full discussion of these emerging data is beyond the scope of this article [40,51,52].”
BackgroundSelf-citationDesideri, G., Kwik-Uribe, C., Grassi, D., Necozione, S., Ghiadoni, L., Mastroiacovo, D., Raffaele, A., Ferri, L., Bocale, R., Lechiara, M. C., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.193060 · Cited by 311
Sex differences in cognitive impairment in Alzheimer’s disease
Laws, K. R., Irvine, K., & Gale, T. M. (2016) · World Journal of Psychiatry · doi:10.5498/wjp.v6.i1.54 · Cited by 307 · cited 1×
“greater attention to muscle mass in men), but a full discussion of these emerging data is beyond the scope of this article [40,51,52].”
BackgroundMatura, S., Fleckenstein, J., Deichmann, R., Engeroff, T., Füzéki, E., Hattingen, E., Hellweg, R., Lienerth, B., Pilatus, U., Schwarz, S., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.135 · Cited by 97 · cited 2×
“Similarly, in people aged 65 years (an age at which about 10% have developed dementia due to AD), brain pathology began between the ages of 35 and 45 years [7].”
BackgroundNutritional interventions for Alzheimer's prevention: a clinical precision medicine approach
Schelke, M. W., Hackett, K., Chen, J. L., Shih, C., Shum, J., Montgomery, M. E., Chiang, G. C., Berkowitz, C., Seifan, A., Krikorian, R., et al. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13070 · Cited by 51 · cited 1×
“, neurodevelopment, academic trajectory, past and current lifestyle patterns, environmental exposures, and life course events) is combined with past medical history and physical/ neurological examination and then interpreted in conjunction with anthropometrics, blood biomarkers (including genetics), and cognitive perf…”
MethodSelf-citationRobinson, L., Dickinson, C., Magklara, E., Newton, L., Prato, L., & Bamford, C. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-018677 · Cited by 26
Cited by
Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021
Porsteinsson, A. P., Isaacson, R. S., Knox, S., Sabbagh, M. N., & Rubino, I. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.23 · Cited by 744
“Following AD diagnosis, a comprehensive approach toward clinical care can be individualized based on the patient’s specific AD risk factors (20, 21).”
Self-citationAlzheimer’s Disease – Why We Need Early Diagnosis
Rasmussen, J., & Langerman, H. (2019) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s228939 · Cited by 501
“8,18 There is a greater likelihood of progression in those with more than one of these risk factors.”
InfluentialPike, K. E., Cavuoto, M. G., Li, L., Wright, B. J., & Kinsella, G. J. (2022) · Neuropsychology Review · doi:10.1007/s11065-021-09522-3 · Cited by 259
Rahman, A., Jackson, H., Hristov, H., Isaacson, R. S., Saif, N., Shetty, T., Etingin, O., Henchcliffe, C., Brinton, R. D., & Mosconi, L. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00315 · Cited by 187
“In order to address the growing AD epidemic, the field is shifting toward early detection and primary and secondary prevention efforts (Isaacson et al., 2018).”
BackgroundSelf-citationUsing the Biopsychosocial Model to Guide Patient-Centered Neurological Treatments
Saxena, A., Paredes-Echeverri, S., Michaelis, R., Popkirov, S., & Perez, D. L. (2022) · Seminars in Neurology · doi:10.1055/s-0041-1742145 · Cited by 53
Metadata
- Authors
- Isaacson, R. S., Ganzer, C. A., Hristov, H., Hackett, K., Caesar, E., Cohen, R., Kachko, R., Meléndez‐Cabrero, J., Rahman, A., Scheyer, O., Hwang, M. J., Berkowitz, C., Hendrix, S., Mureb, M., Schelke, M. W., Mosconi, L., Seifan, A., & Krikorian, R.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2018-11-13
- Volume
- 14
- Issue
- 12
- Pages
- 1663-1673
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2900627486
- Cited by
- 103
- References
- 24
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.